AtaiBeckley (ATAI) Soars to 4-Year High on $3.8B Merger with Eli Lilly

AtaiBeckley climbed to a new four-year high on Thursday, as investors bought into its shares following news that Eli Lilly agreed to acquire the company for up to $3.8 billion.

In intra-day trading, the stock surged to a record high of $7.22 before trimming gains to end the session just up by 33.40 percent at $7.15 apiece.

Under the agreement, AtaiBeckley Inc. (NASDAQ:ATAI) shareholders are expected to receive $6.75 in cash per share, in addition to up to $2.50 per share in contingent value rights, which will be paid only upon the achievement of certain milestones.

While the total consideration of $9.25 represents a potential premium of 72 percent over Wednesday's closing price of $5.36, prior to the announcement, the stock closed just 40-cents higher than the guaranteed payment, signaling that investors appear to be assigning only modest value to its milestone-based payouts.

Under the terms of the CVR, shareholders will expect to receive $1 per share upon the initiation of a phase 3 trial for VLS-01 before the fourth year of the deal's closing.

Another $0.50 per share is expected upon US regulatory approval and DEA rescheduling of BPL-003 before it reaches the fifth anniversary of closing, while a dollar per share will be released upon US regulatory approval and DEA rescheduling of VLS-01 prior to the seventh anniversary of closing.

AtaiBeckley Inc. (NASDAQ:ATAI) and Eli Lilly expect to close the transaction in the third quarter of the year, subject to approval of the former's stockholders and other regulatory approvals.

The acquisition is expected to give Eli Lilly a wider presence in the rapidly evolving market for treatment-resistant depression and other severe psychiatric disorders.

Emerging research indicates that treatment-resistant depression and other serious mental health conditions may involve a loss of synaptic plasticity, the brain's ability to form and strengthen connections in regions critical to mood regulation.

AtaiBeckley Inc.'s (NASDAQ:ATAI) therapies are designed to restore synaptic connectivity and aim to promote the growth of new neural connections, offering a distinct mechanism from conventional antidepressants that primarily target neurotransmitter levels.

"Across our portfolio, we're seeking to demonstrate that psychiatric illness is treatable at its biological root, not just its symptoms," AtaiBeckley Inc. (NASDAQ:ATAI) CEO Srinivas Rao said.

"Lilly's expertise and reach are expected to accelerate that work for people whose conditions have not responded to existing treatments."

Notably, more institutional investors appeared to have increased their exposure in AtaiBeckley Inc. (NASDAQ:ATAI) prior to the acquisition announcement.

Based on Insider Monkey data, 35 hedge funds held positions in its shares in the first quarter of the year, markedly up from only 23 in the previous quarter.

Collectively, the 35 hedge funds have $125 million worth of stake in the company, versus only $96.47 million quarter-on-quarter.

The sharp jump in hedge fund participation signaled that more professional investors are growing more constructive on the company's pipeline even before Eli Lilly's acquisition.

While we acknowledge the potential of ATAI as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock .